Genomic Vision Extends Quest Agreement for Development of LDT for Hereditary Genetic Disease | GenomeWeb

NEW YORK (GenomeWeb News) – French biotech Genomic Vision today announced it and Quest Diagnostics have extended their strategic alliance agreement originally forged in 2011.

Under the terms of the extension, Quest will invest in the planned development of a laboratory-developed test for an undisclosed hereditary genetic disease. The two firms also will collaborate on automating the testing process and improving turnaround times for tests that use Genomic Vision's DNA combing technique.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.